New hope for endometrial cancer: drug combo shows promise in spanish trial

NCT ID NCT06746116

First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 26 times

Summary

This study tests a combination of drugs (durvalumab, chemotherapy, and olaparib) as a first treatment for people in Spain with advanced or recurrent endometrial cancer that has a specific genetic marker (pMMR). The goal is to see if the treatment is safe and helps control the cancer. About 85 participants will be followed for up to 3 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR RECURRENT ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    A Coruña, 15006, Spain

  • Research Site

    Alicante, 03010, Spain

  • Research Site

    Barakaldo, 48903, Spain

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Córdoba, 14004, Spain

  • Research Site

    El Palmar, 30120, Spain

  • Research Site

    Girona, 17007, Spain

  • Research Site

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    Las Palmas de Gran Canaria, 35016, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Madrid, 28046, Spain

  • Research Site

    Madrid, 28807, Spain

  • Research Site

    Málaga, 29010, Spain

  • Research Site

    Pamplona, 31008, Spain

  • Research Site

    Salamanca, 37007, Spain

  • Research Site

    San Sebastián, 20014, Spain

  • Research Site

    Santander, 39008, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Valencia, 46009, Spain

  • Research Site

    Valencia, 46010, Spain

  • Research Site

    Valencia, 46026, Spain

  • Research Site

    Vigo, 36312, Spain

  • Research Site

    Zaragoza, 50009, Spain

Conditions

Explore the condition pages connected to this study.